Single-cell RNA sequencing of psoriatic skin identifies pathogenic Tc17 cell subsets and reveals distinctions between CD8+ T cells in autoimmunity and cancer
- PMID: 33309739
- PMCID: PMC9179181
- DOI: 10.1016/j.jaci.2020.11.028
Single-cell RNA sequencing of psoriatic skin identifies pathogenic Tc17 cell subsets and reveals distinctions between CD8+ T cells in autoimmunity and cancer
Abstract
Background: Psoriasis is an inflammatory, IL-17-driven skin disease in which autoantigen-induced CD8+ T cells have been identified as pathogenic drivers.
Objective: Our study focused on comprehensively characterizing the phenotypic variation of CD8+ T cells in psoriatic lesions.
Methods: We used single-cell RNA sequencing to compare CD8+ T-cell transcriptomic heterogeneity between psoriatic and healthy skin.
Results: We identified 11 transcriptionally diverse CD8+ T-cell subsets in psoriatic and healthy skin. Among several inflammatory subsets enriched in psoriatic skin, we observed 2 Tc17 cell subsets that were metabolically divergent, were developmentally related, and expressed CXCL13, which we found to be a biomarker of psoriasis severity and which achieved comparable or greater accuracy than IL17A in a support vector machine classifier of psoriasis and healthy transcriptomes. Despite high coinhibitory receptor expression in the Tc17 cell clusters, a comparison of these cells with melanoma-infiltrating CD8+ T cells revealed upregulated cytokine, cytolytic, and metabolic transcriptional activity in the psoriatic cells that differed from an exhaustion program.
Conclusion: Using high-resolution single-cell profiling in tissue, we have uncovered the diverse landscape of CD8+ T cells in psoriatic and healthy skin, including 2 nonexhausted Tc17 cell subsets associated with disease severity.
Keywords: CD8(+) T cell; Single-cell RNA sequencing; Smart-seq2; T-cell exhaustion; melanoma; psoriasis.
Copyright © 2020 American Academy of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved.
Conflict of interest statement
Conflict of Interest
T.B. is currently an investigator for Celgene, Janssen, Merck, and Regeneron. She has served as an advisor for Abbvie, Lilly, and Pfizer. M.D.R is a founder and consultant for TRex Bio., a founder of Sitryx Bio., and receives funding from Abbvie, LEO Pharma and TRex Bio.
Figures





References
-
- Lowes MA, Kikuchi T, Fuentes-Duculan J, Cardinale I, Zaba LC, Haider AS, et al. Psoriasis Vulgaris Lesions Contain Discrete Populations of Th1 and Th17 T Cells. J Invest Dermatol [Internet]. 2008;128:1207–11. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0022202X15338537 - PubMed
-
- Reich K, Papp KA, Blauvelt A, Tyring SK, Sinclair R, Thaçi D, et al. Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials. Lancet (London, England) [Internet]. 2017;390:276–88. Available from: http://www.ncbi.nlm.nih.gov/pubmed/28596043 - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases
Research Materials